Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Endo Gives FDA Breathing Room in Bulk Compounding Suit

Jan. 26, 2018, 6:01 PM

Endo International agreed to press pause on its lawsuit against the FDA until March 30 to give the agency time to revise its bulk drug compounding policy.

In response to a joint request by Endo subsidiaries Par Sterile Products LLC, Endo Par Innovation Co., and the agency, Judge Amit P. Mehta of the U.S. District Court for the District of Columbia Jan. 25 stayed Endo’s suit against the Food and Drug Administration. Endo, which owns intellectual property in the septic shock treatment Vasostrict (vasopressin), wants the court to order the FDA to put the kibosh on bulk compounding of ...